Teva Launching Generic Relafen After Court Rules GSK Patent Invalid
Executive Summary
Teva is "immediately" launching generic nabumetone following an Aug. 14 court decision upholding its patent challenge to GlaxoSmithKline's Relafen.
You may also be interested in...
Teva/GSK settle Relafen litigation
All patent litigation between Teva and GSK regarding generics of Relafen (nabumetone) has been settled, Teva says April 30. Teva entered generic nabumetone market in August 2001 with 500 mg and 750 mg tablets following successful Boston federal court challenge of GSK patent (1"The Pink Sheet" Aug. 20, 2001, p. 14)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011